The global leader in hemophilia & hematology studies
Excellent working relationships with KOLs globally
Current knowledge of enrollment rates and global competition
Hemophilia A & B Clinical Trials Experience
- 40 phase I-IV studies conducted in 40+ countries
- 700 sites overall in North America, Latin America, Europe, South Africa, Asia-Pacific, Japan
- 1000 patients enrolled
- Close collaboration and good relationship with sites, including KOLs globally
- 7 FDA inspection and PMDA inspection to PSI sites resulting in drug approval
- Extensive Gene Therapy experience
Braving Gene Therapy
Gene therapy offers the promise of correcting genetic diseases by delivering a functional DNA copy, commonly using viral vectors. Of all the diseases out there, many biotechs have decided to focus their gene therapies in hemophilia.
PSI is one if not the only CRO that has been engaged extensively in gene therapy trials by half a dozen biotech sponsors.
The sheer numbers of innovative hemophilia treatments hint at a brighter future for patients in the next few years. In the words of Jan Hartmann and Stacy Croteau from Harvard Medical School, “hemophilia is now at the precipice of a therapeutic revolution.”
Revolutionary treatments require revolutionary CROs, intolerant of trial delays, accountable for study budgets, knowledgeable of regulatory landscapes throughout the world. Even more impor- tantly, the CRO must have developed tight and effective working relationships with hemophilia sites around the world. These rela- tionships must have stood the test of timely patient enrollment and many FDA inspections resulting in drug approvals.
We invite you to join us on a dedicated, complex and exciting journey to a better future of hemophilia patients.
PSI’s key differentiator is our ability to plan and execute complex clinical trials on time, saving our customers millions of development dollars.
“Thanks again to all the PSI teams that helped us in completing enrollment in our pivotal Phase III trials -- safe to say we could have never done it without PSI.”
VP, Clinical Operations and Data Management
The PSI Advantage
Inflammatory Bowel Diseases (IBD)
Crohns’ Disease, Ulcerative Colitis and other IBDs.
Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer and other Oncology indications.
Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.
Antimicrobial and Antifungal infections and other ID.
Multiple Sclerosis, Spasticity and other neurological indications.
Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).